Genome Editing in Human iPS Cells to Study and Cure Disease
Human iPS (induced pluripotent stem) cells have the potential to allow us to study diseases in virtually any type of human cell, and develop cell transplantation-based therapies. Our team is developing and improving genome editing technology in iPS cells. We are developing novel isogenic iPS cell-based disease models, and correcting mutations in iPS cells from patients, a critical step in transplantation-based therapies. Our current focus is on diseases affecting cardiomyocytes and hepatocytes. →More
News
2025. 4. 3. Gou Takahashi and Yuichiro Miyaoka contribute to the book, CRISPR-Cas Methods : Volume 3
2025. 4. 1. Ittetsu Nakajima is awarded the ISSCR Travel Award!
2025. 4. 1. Moe Sato and Haruka Nakayama join the lab as a graduate student and an intern, respectively!
2025. 3. 2. Lab ski & snowboard trip to Madarao
2025. 3. 1. Daisuke Matsumoto comments in Springer Nature Japan Research Advisory Forum 2024 (in Japanese).
2024. 12. 27. Kayoko Shinozaki and Yuga Yasuda sre awarded the Belle Foundation Fellowship!!
2024. 11. 1. Noa Tozawa joins the lab as an Intern!
2024. 10. 4. Lab trip to the Nakatsugawa trout fishing ground.
2024. 10. 1. Hiroto Serita and Ryo Shiraki join the lab as Interns!
2024. 9. 19. Isolation and analysis of >1,000 genome-edited iPS cell clones in collaboration with Yamaha Mortor is out in bioRxiv.
2024. 9. 2. Daisuke Matsumoto joins the lab as a Staff Scientist!
Upcoming
2025. 7.17. Membrane Physiology Symposium Japan 2025@RCAST, U-Tokyo (Talk)
2025. 9.19-21. 32th The Bayer Scholarship for Cardiovascular Research Conference @Kochi
2024. 12. 5. Seminar at Ome Nursing School